Snowflake Inc. (NYSE:SNOW) is one of the AI Stocks on Market Radar. On December 23, Baird reiterated the stock as “Outperform” with a price target of $270. Firm analysts see the rumored $1B acquisition of privately-held Observe as strategically logical, with low integration risk. “Yesterday evening, rumors surfaced (via an article published by The Information) that SNOW could be in talks to acquire privately-held Observe. The rumored ~$1 billion price tag would be SNOW’s biggest acquisition to-date, but w ...

Thailand and Cambodia have agreed to a ceasefire, marking a crucial step towards resolving their long-standing border dispute.According to a joint statement signed by the defense ministers of both Southeast Asian nations, the agreement was reached at the 3rd Special General Border Committee (GBC) meeting on Saturday.The ceasefire, which goes into effect at noon on Saturday, prohibits all military operations, including assaults on infrastructure and civilians.Both sides have committed to not increasing their ...

市场动态与筛选标准 - 根据MarketBeat的股票筛选工具，今日值得关注的五只小盘股为Dynavax Technologies、Spring Valley Acquisition、Omeros、SOBR Safe和AlphaVest Acquisition [2] - 小盘股通常指市值介于约3亿美元至20亿美元之间的上市公司股票，具体范围因指数提供商而异 [2] - 投资者认为小盘股相比中大盘股具有更高的增长潜力，但也伴随着更大的波动性、更低的流动性以及更高的风险 [2] - 这些公司在过去几天内是所有小盘股中美元交易额最高的 [2] Dynavax Technologies (DVAX) 公司概况 - 公司是一家商业阶段的生物制药公司，专注于在美国开发和商业化疫苗 [3] - 其上市产品为HEPLISAV-B，这是一种用于预防18岁及以上成年人感染所有已知乙型肝炎病毒亚型的乙肝疫苗，在美国和欧洲市场销售 [3] Omeros (OMER) 公司概况 - 公司是一家临床阶段的生物制药公司，致力于发现、开发和商业化针对免疫性疾病的小分子及蛋白质疗法，包括补体介导的疾病、癌症以及成瘾和强迫症 [4] - 其主要在研产品Narsoplimab (OMS721/MASP-2) 已完成针对造血干细胞移植相关血栓性微血管病的关键试验，正在进行治疗免疫球蛋白A肾病的三期临床试验，以及治疗COVID-19的二期临床试验 [4] SOBR Safe (SOBR) 公司概况 - 公司是一家硬件和软件公司，在北美开发非侵入性酒精检测、生物特征身份验证以及实时云端警报和报告系统 [5] - 公司提供的产品包括SOBRcheck（一种固定的身份识别和酒精监测产品）以及SOBRsure（一种经皮酒精检测可穿戴腕带） [5] 其他提及公司 - 文章提及了特殊目的收购公司Spring Valley Acquisition (SV) 和 AlphaVest Acquisition (ATMV)，但未提供其具体业务描述 [3][5]

NVIDIA Corporation (NASDAQ:NVDA) is one of the AI Stocks Investors Are Watching. On December 19, Bernstein analyst Stacy Rasgon reiterated an “Outperform” rating on the stock with a $275 price target. According to the firm, Nvidia is trading at 25-times forward earnings, which puts the stock in the eleventh percentile of valuation over the past 10 years. "Just How Cheap Is It? Nvidia’s performance has been somewhat challenged as of late...While putting up decent overall performance (with the shares up ~3 ...

Oracle Corporation (NYSE:ORCL) is one of the AI Stocks Investors Are Watching. On December 22, Wells Fargo reaffirmed its ‘Overweight’ rating on the stock with a $280 price target. Firm analysts believe that artificial-intelligence related concerns related to the stock are overblown and that the stock remains undervalued. Analyst Michael Turrin noted that sentiment for Oracle has skewed more negative in the near term. Some analysts, in particular, have been worrying about Oracle's high OpenAI exposure and ...

Apple Inc. (NASDAQ:AAPL) is one of the AI Stocks Investors Are Watching. On December 23, JPMorgan reiterated the stock as “Overweight” and a $305 price target.  According to the firm’s survey checks, Apple’s iPhone 17 lead times have moderated by a few days this week from last week. “In Week 15 of our Apple Product Availability Tracker, lead times across the iPhone 17 series moderated by three days, relative to unchanged lead times observed from Wk14 to Wk15 in the prior year for iPhone 16, with average l ...

Xperi (NYSE:XPER – Get Free Report) and Mega Fortune (NASDAQ:MGRT – Get Free Report) are both small-cap services companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation. Get Xperi alerts: Earnings and ValuationThis table compares Xperi and Mega Fortune”s top-line revenue, earnings per share and valuation.Gross RevenuePrice/Sales RatioNet IncomeEarning ...

分析师评级与目标价 - 九家研究机构给予公司股票“适度买入”的共识评级 其中一位分析师给出卖出评级 七位给出买入评级 一位给出强力买入评级 [2] - 过去一年覆盖该股票的券商给出的平均12个月目标价为3.8571美元 [2] - 近期多家机构发布研究报告 D Boral Capital重申“买入”评级 目标价2美元 HC Wainwright重申“买入”评级 目标价4美元 Benchmark将目标价从14美元下调至7美元 并给出“投机性买入”评级 Weiss Ratings重申“卖出”评级 Wall Street Zen将评级从“卖出”上调至“持有” [3] 股价与财务表现 - 公司股价在周五开盘报0.31美元 当日股价上涨10.4% [4] - 公司五十日移动平均线为0.55美元 两百日移动平均线为0.51美元 [4] - 公司市值为3531万美元 市盈率为-0.67 贝塔系数为-0.02 过去12个月股价最低为0.25美元 最高为2.17美元 [4] - 公司最近一期财报显示每股收益为-0.06美元 超出市场普遍预期的-0.11美元 超出幅度为0.05美元 [5] - 股票研究分析师预计公司本财年每股收益为-0.97美元 [5] 机构持仓变动 - 多家对冲基金近期买卖了公司股票 Geode Capital Management LLC在第二季度增持6.9% 目前持有448,202股 价值17.1万美元 [6] - NewEdge Advisors LLC在第一季度新建仓位 价值约5.8万美元 XTX Topco Ltd在第二季度新建仓位 价值约3.1万美元 Lido Advisors LLC在第三季度新建仓位 价值约3.7万美元 [6] - Millennium Management LLC在第三季度增持15.0% 目前持有1,711,221股 价值63.1万美元 [6] - 机构投资者和对冲基金合计持有公司63.18%的股份 [6] 公司业务概况 - 公司是一家专业制药公司 专注于在美国及部分国际市场收购、开发和商业化处方药产品 [7] - 公司成立于2002年 总部位于佛罗里达州科勒尔盖布尔斯 其策略是针对推广不足、专利过期的药物 通过开发新剂型来提高患者依从性和治疗效果 [7] - 公司核心活动包括识别FDA批准的候选药物 针对儿科和孤儿药等小众或服务不足的患者群体进行剂型开发 并支持监管申报 [8]

Plains All American Pipeline (NASDAQ:PAA – Get Free Report) is one of 16 public companies in the “Pipelines, Except Natural Gas” industry, but how does it weigh in compared to its rivals? We will compare Plains All American Pipeline to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk. Get Plains All American Pipeline alerts: DividendsPlains All American Pipeline pays an annual dividend of $1.52 per share ...

Plains All American Pipeline (NASDAQ:PAA – Get Free Report) is one of 16 public companies in the “Pipelines, Except Natural Gas” industry, but how does it contrast to its rivals? We will compare Plains All American Pipeline to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, risk, profitability, earnings and valuation. Get Plains All American Pipeline alerts: Institutional and Insider Ownership41.8% of Plains All American Pipeline shares are held ...